NCT06982508View on ClinicalTrials.gov

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Antioxidant Absorption
Interventions
DRUG

Obicetrapib 10mg

Active Drug

DRUG

Placebo

Placebo Control

Trial Locations (1)

33169

RECRUITING

Excellence Medical Research, Miami Gardens

Sponsors
All Listed Sponsors
collaborator

MB Clinical Research and Consulting LLC

UNKNOWN

lead

NewAmsterdam Pharma

INDUSTRY

NCT06982508 - Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | Biotech Hunter | Biotech Hunter